Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 15 - Drugs for genital or sexual disorders; Contraceptives
Patents for A61P 15 - Drugs for genital or sexual disorders; Contraceptives (55,635)
08/2003
08/14/2003US20030153606 Antiproliferative agents for treating adipocyte differentiation, cancer, osteoarthritis, rheumatoid arthritis, Crohn's Disease or Inflammatory Bowel Disease
08/14/2003US20030153587 Such as 3-((3-bromo-4-hydroxyphenyl)methyl)-5-ethyl-7,8-dihydro-2-(tetrahydro-2H -pyran-4-yl)amino)-3H-imidazo(2,1-b) purin-4(5H)-one for treating sexual disorders
08/14/2003US20030153576 Such as amino-indazoles for treatment of central nervous system disorders
08/14/2003US20030153575 Tetracyclic diketopiperazine compounds as pdev inhibitors
08/14/2003US20030153568 Serine/threonine and tyrosine kinases inhibitors
08/14/2003US20030153540 For improving health in a woman having elevated sex hormone binding globulin levels, or who is receiving oral estrogen supplementation
08/14/2003US20030153500 Use of EGF to inhibit pathogenic infections
08/14/2003US20030153072 Culturing spermatogonial stem cells in the presence of BMP8 (bone morphogenetic protein-8) or a biologically active fragment or an agonist to effect proliferation of mammal spermatogonial stem cells
08/14/2003US20030153018 Methods and compositions for treating cancer using 2192, 2193, 6568, 8895, 9138, 9217, 9609, 9857, 9882, 10025, 20657, 21163, 25848, 25968, 32603, 32670, 33794, 54476 and 94710
08/14/2003US20030152650 Pharmaceutical composition for prevention and treatment of premature ejaculation and/or hypersensitivity of sexual stimulation
08/14/2003US20030152643 Combination of an alpha-adrenergic antagonist and a nitrogen oxide donor for treating female sexual dysfunctions
08/14/2003CA2475767A1 Opioid receptor active 4-(3-hydroxyphenyl) or 4-(3-alkoxyphenyl)-1,2,4-triazole compounds
08/14/2003CA2475377A1 Use of pde5 inhibitors such as sildenafil in the treatment of polycystic ovary syndrome
08/14/2003CA2475093A1 Dihydro-thia-phenanthrene-carbonyl-guanidines, method for the production thereof, use thereof as a medicament or diagnostic reagent
08/14/2003CA2474921A1 Pharmaceutical tablet
08/14/2003CA2474283A1 Amino acid sequences capable of facilitating penetration across a biological barrier
08/14/2003CA2474190A1 Pharmaceutical dosage form for mucosal delivery
08/13/2003EP1334972A1 Non-peptide compounds affecting the action of gonadotropin-releasing hormone (GnRH)
08/13/2003EP1334725A2 Estroprogestative contraceptive composition
08/13/2003EP1334201A2 Dna expression vectors
08/13/2003EP1334194A2 Imaging, diagnosis and treatment of disease
08/13/2003EP1334102A1 Bombesin receptor antagonists
08/13/2003EP1334100A1 Bombesin receptor antagonists
08/13/2003EP1333862A2 Methods of and pharmaceutical compositions for improving implantation of embryos
08/13/2003EP1333858A1 Vaccines with enhanced immune response and methods for their preparation
08/13/2003EP1333829A1 Treatment of sexual dysfunction using bombesin antagonists
08/13/2003EP1333827A2 Estrogen receptor modulators
08/13/2003EP1333824A2 Treatment of sexual dysfunction
08/13/2003EP1333821A2 Novel uses of combined selective dopamine d2 receptor antagonists and 5-ht1a receptor agonists
08/13/2003EP1333719A2 Corticotropin releasing factor receptor 2 deficient mice and uses thereof
08/13/2003EP1152768B1 Treatment of chronic viral infections with m. vaccae
08/13/2003EP1073658B1 Pyrazolopyrimidinone cgmp pde5 inhibitors for the treatment of sexual dysfunction
08/13/2003EP0879233B1 Chinoline and benzimidazole derivatives as bradykinin agonists
08/13/2003CN1436237A Nucleotide sequences involved in increasing or decreasing mammalian ovulation rate
08/13/2003CN1436235A Anti-angiogenic polypeptides
08/13/2003CN1436192A HMG-CoA reductase inhibitors and method
08/13/2003CN1436174A HMG-CoA reductase inhibitors and their use as medicaments for treatment of cholesterol related diseases
08/13/2003CN1436081A Starter kit for low dose oral contraceptives
08/13/2003CN1435243A Medicine for treating functional metrorrhagia and preparing process thereof
08/13/2003CN1435229A ÔÇ£ErbeimuÔÇØ capsule preparing process thereof
08/13/2003CN1435223A Externally applied medicinal stasis-and swelling-eliminating powder for treating chronic pelvic inflammation
08/13/2003CN1435222A Medicine for treating woman diseases
08/13/2003CN1435215A Zaizao Pill for treating woman diseases
08/13/2003CN1435210A Skin Chinese medicine disinfectant liquid and use thereof for suppressing prospermia
08/13/2003CN1435196A Chinese medicine preparation for treating sexual dysfunction and preparing method thereof
08/13/2003CN1117759C Steroid, its preparation method, medicine composition and use thereof
08/12/2003US6605637 Lipoic acid derivatives, their preparation, and pharmaceutical compositions containing them
08/12/2003US6605632 Affinity for melatonin receptors
08/12/2003US6605607 Antihypertensives; hyperprolactinaemia related conditions; certain central nervous system disorders
08/12/2003US6605592 Protein HOFNF53
08/12/2003CA2418712A1 Non-peptide gnrh agents, pharmaceutical compositions, and methods for their use
08/12/2003CA2296373C Composition and method for treating penile erectile dysfunction
08/07/2003WO2003065046A2 Diagnostics and therapeutics for diseases associated with a new human 5-ht6 receptor
08/07/2003WO2003064629A2 Therapeutic polypeptides, nucleic acids encoding same, and methods of use
08/07/2003WO2003064596A2 Desaturase genes, enzymes encoded thereby, and uses thereof
08/07/2003WO2003064463A2 Pluripotency determining factors and uses thereof
08/07/2003WO2003064460A2 Two gonadotropin releasing hormones and a method to isolate the same
08/07/2003WO2003064443A2 New corticosteroids
08/07/2003WO2003064429A1 Thienopyrimidines, process for preparing the same and use thereof
08/07/2003WO2003064425A1 N-substituted spiropiperidine compounds as ligands for orl-1 receptor
08/07/2003WO2003064423A1 Aza-arylpiperazines
08/07/2003WO2003064418A1 Anticholinergic agents, method for producing the same and use thereof as medicaments
08/07/2003WO2003064402A1 Treatment of male sexual dysfunction
08/07/2003WO2003064387A2 Substituted indoles as alpha-1 agonists
08/07/2003WO2003064376A1 Substituted methylene amide derivatives as modulators of protein tyrosine phosphatases (ptps)
08/07/2003WO2003063893A2 Fgfr agonists
08/07/2003WO2003063892A1 Use of apelin
08/07/2003WO2003063875A1 Use of pde5 inhibitors in the treatment of scarring and fibrosis
08/07/2003WO2003063859A1 Suppression of cartilage degradation via the estrogen receptor
08/07/2003WO2002055541A3 Peptides having inhibiting activity on the production of nitric oxide
08/07/2003WO2002024222A3 Ligands for g protein coupled receptors and methods of using them
08/07/2003WO2002002593A3 Modulators of cellular proliferation and angiogenesis, methods for use and identification thereof
08/07/2003WO2002000172A3 Methods for using tetanus toxin for benificial purposes in animals (mammals)
08/07/2003US20030149268 Administering non-steroidal 9-pyrido(3,2-g)quinoline compounds to the mammal for affecting androgen receptor activity
08/07/2003US20030149108 Linked biaryl compounds
08/07/2003US20030149094 Compositions comprising ether compounds and pharmaceutical uses therefor
08/07/2003US20030149081 For therapy and prophylaxis of asthma, seasonal and perennial allergic rhinitis, sinusitus, conjunctivitis, food allergy, scombroid poisoning, psoriasis, urticaria, pruritus, eczema, inflammatory bowel disease, atherosclerosis
08/07/2003US20030149067 Crystallisation of the desired crystalline form from a toluene/diethyl ether mixture comprising raw cabergoline, followed by recovery and drying of the resulting crystals
08/07/2003US20030149056 3-cyanoquinolines as inhibitors of EGF-R and HER2 kinases
08/07/2003US20030149033 For prophylaxis and therapy of cerebrovascular diseases such as cerebral ischemia, stroke, reperfusion damage, brain trauma, edemas, cerebral thrombosis, dementia and Alzheimer's diseass
08/07/2003US20030149001 2-(Pyridin-2-ylamino)-pyrido[2,3-d]pyrimidin-7-ones
08/07/2003US20030148946 Method and compositions for preventing hormone induced adverse effects
08/07/2003US20030148934 Human growth factor modulators (GFMO) polynucleotides which identify and encode GFMO; amino acid sequences, expression vectors, host cells, antibodies, agonists, and antagonists; anticarcinogenic agents; fibrotic disorders
08/07/2003US20030147937 Di-myo-inositol phosphate, cyclic 2,3 diphosphoglycerate, 1,1-di- glycerol phosphate, mannosylglycerate, mannosyl glyceramide and/or di-mannosyl-di-inositol phosphate; protecting organisms, organs, tissues, cells from oxidation
08/07/2003US20030147905 Administering an oligopeptide for immunotherapy
08/07/2003CA2714295A1 Desaturase genes, enzymes encoded thereby, and uses thereof
08/07/2003CA2474852A1 Use of pde5 inhibitors in the treatment of scarring and fibrosis
08/07/2003CA2474649A1 Therapeutic polypeptides, nucleic acids encoding same, and methods of use
08/07/2003CA2474590A1 Treatment of male sexual dysfunction
08/07/2003CA2473810A1 Fgfr agonists
08/07/2003CA2473803A1 Substituted indoles as alpha-1 agonists
08/07/2003CA2473249A1 New corticosteroids
08/07/2003CA2466915A1 N-substituted spiropiperidine compounds as ligands for orl-1 receptor
08/06/2003EP1332372A2 Net, a transcription factor of the tcf family, as regulator of angiogenic factor expression
08/06/2003EP1332146A2 Spiro-pyrimidine-2,4,6-trione metalloproteinase inhibitors
08/06/2003EP1332144A1 Indole derivatives as pde5-inhibitors
08/06/2003EP1332136A2 Pyrimidine-2,4,6-trione metalloproteinase inhibitors
08/06/2003EP1331943A2 Nucleic acid molecules and polypeptides for immune modulation
08/06/2003EP1331935A2 Derivatives of tryptamine and analogous compounds, and pharmaceutical formulations containing them
08/06/2003EP1165544B1 Substituted 1,4-dihydroindeno[1,2-c]pyrazoles as inhibitors of tyrosine kinase
1 ... 350 351 352 353 354 355 356 357 358 359 360 361 362 363 364 365 366 367 368 369 370 ... 557